Difference between revisions of "Volunteer Assignments and Opportunities"

From Compendium of Cancer Genome Aberrations
Jump to navigation Jump to search
[unchecked revision][unchecked revision]
Line 332: Line 332:
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|Precursor Lymphoid Neoplasms ||'''''Overview'''''|| ||Yassmine Akkari (YA)
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic  Abnormalities||'''''Overview'''''|| ||YA
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2);  BCR-ABL1||Disease|| ||YA
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|B-Lymphoblastic  Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged||Disease|| ||YA
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|B-Lymphoblastic  Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1||Disease|| ||YA
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|B-Lymphoblastic  Leukemia/Lymphoma with Hyperdiploidy||Disease|| ||YA
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|B-Lymphoblastic  Leukemia/Lymphoma with Hypodiploidy||Disease|| ||YA
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|B-Lymphoblastic  Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3||Disease|| ||YA
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|B-Lymphoblastic  Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1||Disease|| ||YA
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|B-Lymphoblastic  Leukemia/Lymphoma, BCR-ABL1-Like||Disease|| ||YA
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|B-Lymphoblastic  Leukemia/Lymphoma with iAMP21||Disease|| ||YA
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|B-Lymphoblastic  Leukemia/Lymphoma, Not Otherwise Specified||Disease|| ||YA
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|T-Lymphoblastic Leukemia/Lymphoma||'''''Overview'''''|| ||YA
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|Early T-Cell Precursor Lymphoblastic Leukemia||Disease|| ||YA
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
|NK-Lymphoblastic Leukemia/Lymphoma||Disease|| ||YA
 
|
 
|
 
|
 
|
 
|-
 
|-
|Example||Example|| ||Example
+
| || || ||
 
|
 
|
 
|
 
|

Revision as of 17:23, 21 May 2020

Disease Page Type Author Associate Editor Author Content (Pending or Complete) Editor Reviewed (Date)
Myeloproliferative Neoplasms (MPN) Overview Fabiola Quintero-Rivera (FQR)
Chronic Myeloid Leukemia (CML), BCR-ABL1-Positive Disease FQR
Chronic Neutrophilic Leukemia (CNL) Disease FQR
Polycythaemia Vera (PV) Disease FQR
Primary Myelofibrosis (PMF) Disease FQR
Essential Thrombocythaemia (ET) Disease FQR
Chronic Eosinophilic Leukemia, Not Otherwise Specified Disease FQR
Myeloproliferative Neoplasm (MPN), Unclassifiable Disease FQR
Mastocytosis Overview FQR
Cutaneous Mastocytosis Disease FQR
Systemic Mastocytosis Disease FQR
Mast Cell Sarcoma Disease FQR
Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2 Overview FQR
Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement Disease FQR
Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement Disease FQR
Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement Disease FQR
Myeloid/Lymphoid Neoplasms with PCM1-JAK2 Disease FQR
Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) Overview FQR
Chronic Myelomonocytic Leukemia (CMML) Disease FQR
Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative Disease FQR
Juvenile Myelomonocytic Leukemia (JMML) Disease FQR
Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) Disease FQR
Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable Disease FQR
Myelodysplastic Syndromes (MDS) Overview FQR
Myelodysplastic Syndrome (MDS) with Single Lineage Dysplasia Disease FQR
Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS) Disease FQR
Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia Disease FQR
Myelodysplastic syndrome with multilineage dysplasiaMyelodysplastic Syndrome (MDS) with Multilineage Dysplasia Disease FQR
Myelodysplastic Syndrome (MDS) with Excess Blasts Disease FQR
Myelodysplastic Syndrome (MDS) with Isolated del(5q) Disease FQR
Myelodysplastic Syndrome (MDS), Unclassifiable Disease FQR
Refractory Cytopenia of Childhood Disease FQR
Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms Overview Jennelle Hodge (JH)
Myeloid Neoplasms with Germline Predisposition Overview JH
Acute Myeloid Leukaemia with Germline CEBPA Mutation Disease JH
Myeloid Neoplasms with Germline DDX41 Mutation Disease JH
Myeloid Neoplasms with Germline RUNX1 Mutation Disease JH
Myeloid Neoplasms with Germline ANKRD26 Mutation Disease JH
Myeloid Neoplasms with Germline ETV6 Mutation Disease JH
Myeloid Neoplasms with Germline GATA2 Mutation Disease JH
Acute Myeloid Leukemia (AML) with Recurrent Genetic Abnormalities Overview JH
Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1 Disease JH
Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 Disease JH
Acute Promyelocytic Leukemia (APL) with PML-RARA Disease JH
Acute Myeloid Leukemia (AML) with t(9;11)(p21.3;q23.3); KMT2A-MLLT3 Disease JH
Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34.1); DEK-NUP214 Disease JH
Acute Myeloid Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM Disease JH
Acute Myeloid Leukemia (AML) Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1 Disease JH
Acute Myeloid Leukemia (AML) with BCR-ABL1 Disease JH
Acute Myeloid Leukemia (AML) with Mutated NPM1 Disease JH
Acute Myeloid Leukemia (AML) with Biallelic Mutations of CEBPA Disease JH
Acute Myeloid Leukemia (AML) with Mutated RUNX1 Disease JH
Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes Disease JH
Therapy-Related Myeloid Neoplasms Disease JH
Acute Myeloid Leukemia (AML), Not Otherwise Specified Overview JH
Acute Myeloid Leukemia (AML) with Minimal Differentiation Disease JH
Acute Myeloid Leukemia (AML) without Maturation Disease JH
Acute Myeloid Leukemia (AML) with Maturation Disease JH
Acute Myelomonocytic Leukemia Disease JH
Acute Monoblastic and Monocytic Leukemia Disease JH
Pure Erythroid Leukemia Disease JH
Acute Megakaryoblastic Leukemia (AMKL) Disease JH
Acute Basophilic Leukemia Disease JH
Acute Panmyelosis with Myelofibrosis Disease JH
Myeloid Sarcoma Disease JH
Myeloid Proliferations Associated with Down Syndrome Overview JH
Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome Disease JH
Myeloid Leukemia Associated with Down Syndrome Disease JH
Blastic Plasmacytoid Dendritic Cell Neoplasm Disease JH
Acute Leukemias of Ambiguous Lineage Overview JH
Acute Undifferentiated Leukemia Disease JH
Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 Disease JH
Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged Disease JH
Mixed Phenotype Acute Leukemia (MPAL), B/Myeloid, Not Otherwise Specified Disease JH
Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified Disease JH
??Mixed-Phenotype Acute Leukaemia, Not Otherwise Specified (NOS), Rare Types Disease JH
??Acute Leukaemias of Ambiguous Lineage, Not Otherwise Specified (NOS) Disease JH
Precursor Lymphoid Neoplasms Overview Yassmine Akkari (YA)
B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities Overview YA
B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1 Disease YA
B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged Disease YA
B-Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1 Disease YA
B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy Disease YA
B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy Disease YA
B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3 Disease YA
B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1 Disease YA
B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like Disease YA
B-Lymphoblastic Leukemia/Lymphoma with iAMP21 Disease YA
B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified Disease YA
T-Lymphoblastic Leukemia/Lymphoma Overview YA
Early T-Cell Precursor Lymphoblastic Leukemia Disease YA
NK-Lymphoblastic Leukemia/Lymphoma Disease YA
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example